Company intelligence / Profile preview
Speratum Biopharma
Dover, Delaware, United Statessperatum.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead candidate NM‑198 has demonstrated potent tumor-suppressive effects across multiple solid tumor models preclinically. The company holds patents covering use of miR‑198 against several cancers. IND-enabling studies are ongoing; no clinical results yet reported.
- Therapeutic areas
- Oncology
- Modalities
- microRNA (miRNA)-based therapeutics (notably miR-198 mimics)Oligonucleotides (including siRNA and antisense oligonucleotides)mRNA-based medicinesGene editing solutions
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Speratum Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Speratum Biopharma.